HBOC

HBOC
Name	Hereditary Breast and Ovarian Cancer
Synonyms	HBOC syndrome
Field	Oncology, Genetics
Genes	BRCA1, BRCA2, PALB2, TP53
Onset	Variable
Prognosis	Variable; increased cancer risk

HBOC

Hereditary Breast and Ovarian Cancer (HBOC) is an inherited cancer susceptibility syndrome characterized chiefly by elevated risks for breast and ovarian malignancies. It arises from germline pathogenic variants in high-penetrance tumor suppressor genes and is relevant across clinical oncology, genetic counseling, and public health screening programs. Management integrates risk assessment, molecular diagnostics, surgical oncology, medical oncology, and psychosocial support.

Definition and Nomenclature

HBOC denotes a familial cancer predisposition first defined through epidemiologic aggregation of early-onset breast cancer and ovarian cancer in pedigree studies conducted alongside population surveys by groups such as the National Cancer Institute, World Health Organization, and academic centers like Memorial Sloan Kettering Cancer Center and Mayo Clinic. Nomenclature evolved from descriptive family-based labels to gene-centric terms after landmark gene discoveries at institutions including Myriad Genetics and laboratories led by investigators associated with University of Utah and University of Pennsylvania. Clinical practice guidelines issued by bodies such as the American College of Medical Genetics and Genomics and National Comprehensive Cancer Network standardize use of the HBOC label for counseling, testing, and management.

Genetics and Molecular Pathogenesis

The canonical genetic etiology involves germline loss-of-function variants in BRCA1 and BRCA2, identified through linkage and positional cloning studies led by research teams connected to University of California, San Francisco and Institute Curie. Additional moderate-penetrance contributors include PALB2, CHEK2, ATM, and rare variants in TP53 described in contexts overlapping with syndromes recognized by St Jude Children's Research Hospital and Great Ormond Street Hospital. Pathogenic variants impair homologous recombination DNA repair, a pathway elucidated by investigators associated with Cold Spring Harbor Laboratory and Broad Institute, leading to genomic instability, copy-number alterations, and somatic mutations analogous to signatures characterized by consortia such as The Cancer Genome Atlas. Founder effects documented in populations like those studied by teams at The Hebrew University of Jerusalem, McGill University, and University of Toronto explain high allele frequencies in some groups; examples include Ashkenazi Jewish founder variants cataloged by geneticists at Hebrew University.

Clinical Presentation and Epidemiology

Individuals with HBOC typically present with early-onset invasive ductal carcinoma, triple-negative breast tumors, high-grade serous ovarian carcinoma, or male breast cancer, patterns described in cohort studies from centers such as Johns Hopkins Hospital, Royal Marsden Hospital, and Princess Margaret Hospital. Lifetime breast cancer risk for BRCA1/BRCA2 carriers is substantially elevated in epidemiologic analyses by International BRCA1/2 Carrier Cohorts and cancer registries like Surveillance, Epidemiology, and End Results Program; ovarian cancer risk is disproportionately higher for BRCA1 carriers. Geographic and ethnic variation in prevalence and phenotype has been reported by investigators affiliated with Mayo Clinic, University College London, and Karolinska Institutet, reflecting founder mutations, screening practices, and population demographics tracked by public health agencies including Centers for Disease Control and Prevention.

Diagnosis and Genetic Testing

Diagnostic evaluation begins with pedigree assessment using criteria promulgated by organizations such as the American Society of Clinical Oncology and European Society for Medical Oncology, followed by molecular testing approaches offered by commercial and academic laboratories like Ambry Genetics, Invitae, and university reference labs at University of Cambridge. Testing strategies include single-gene sequencing, multigene panels, copy-number analysis, and variant classification systems guided by standards from American College of Medical Genetics and Genomics and curated variant databases maintained by groups like ClinVar and Human Gene Mutation Database. Population screening initiatives piloted by teams at Population Health Research Institute and Kaiser Permanente inform debates about cascade testing, while legal and policy contexts influenced by rulings such as those from the United States Supreme Court affect laboratory practice.

Management and Risk-Reduction Strategies

Risk management options derive from clinical trials and guideline statements by authorities including National Comprehensive Cancer Network, Society of Gynecologic Oncology, and American College of Obstetricians and Gynecologists. Primary prevention choices include risk-reducing salpingo-oophorectomy and prophylactic bilateral mastectomy studied in cohorts at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Surveillance strategies encompass enhanced imaging with digital mammography, breast magnetic resonance imaging protocols refined at Mayo Clinic, and ovarian cancer surveillance approaches evaluated in multicenter trials coordinated by Gynecologic Oncology Group. Pharmacologic risk reduction with agents such as selective estrogen receptor modulators was advanced through randomized trials led by groups at National Cancer Institute and Dana-Farber Cancer Institute. Emerging therapies exploiting homologous recombination deficiency, notably PARP inhibitors developed by companies like AstraZeneca and tested in trials organized by cooperative groups including European Organisation for Research and Treatment of Cancer, have transformed treatment paradigms.

Psychological, Ethical, and Social Considerations

Genetic risk disclosure and management raise psychosocial issues studied by behavioral researchers at Harvard University, Stanford University, and University of Michigan. Ethical considerations involve informed consent frameworks from bioethics centers like Kennedy Institute of Ethics and privacy protections shaped by legislation such as the Health Insurance Portability and Accountability Act and the Genetic Information Nondiscrimination Act. Social determinants affecting access to testing and interventions have been analyzed by public health scholars at Johns Hopkins Bloomberg School of Public Health and London School of Hygiene & Tropical Medicine, prompting policy responses from ministries and agencies including National Institutes of Health and regional health services like NHS England.

Category:Genetic cancer syndromes